Ascendis Pharma A/S
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +9.9% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 34.7x | Better than 17% |
| Forward P/E | 37.6x | Better than 12% |
| Price / Sales | 14.5x | Better than 7% |
| P/E vs own 5-yr range | 94th pctl | Better than 10% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 86.8% | Better than 95% |
| Operating margin | -18.9% | Better than 13% |
| Net margin | -31.7% | Better than 10% |
| Return on equity | -818.4% | Better than 1% |
| Return on invested capital | -71.6% | Better than 4% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -0.2% | Better than 73% |
| 6-month return | 2.3% | Better than 60% |
| 12-month return (ex latest month) | 15.4% | Better than 53% |
| Distance below 52-week high | 10.4% | Better than 82% |
Financial Health D
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.0x | Better than 21% |
| Debt to assets | 66.9% | Better than 6% |
| Interest coverage | -1.6x | Better than 21% |
| Free cash flow / net income | 125.4% | Better than 55% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 94.4% | Better than 77% |
| Upside to average target | 22.9% | Better than 38% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 255.96
- Open
- 255.44
- Day range
- 251.55 - 256.65
- Avg price
- 253.44
- Volume
- 602.90K
- Turnover
- 152.80M
- Turnover ratei
- 0.92%
- Volume ratioi
- 0.73
- Amplitudei
- 1.99%
- 52-week rangei
- 188.08 - 282.15
Valuation
- P/Ei
- -61.28
- P/E (TTM)i
- 34.65
- P/Bi
- 10.07
- EPSi
- -4.12
- Book value / shi
- 25.09
- Net profit
- -271.37M
- Net assets
- 1.65B
Share structure
- Market cap
- 16.63B
- Float capi
- 16.62B
- Shares out
- 65.80M
- Float sharesi
- 65.77M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-01-28
10.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-92.89M net over the window
Short interest
- Shares short
- 3.00M
- % of floati
- 4.56%
- Days to coveri
- 4.99
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Ascendis Pharma A/S (ASND)?
Ascendis Pharma A/S last traded at 252.73. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Ascendis Pharma A/S's market cap?
About 16.63B.
What is the P/E ratio of Ascendis Pharma A/S?
The trailing twelve-month P/E is 34.65. The Valuation tab shows it against the stock's own five-year range.
Does Ascendis Pharma A/S pay a dividend?
Ascendis Pharma A/S does not currently pay a regular dividend.
Is Ascendis Pharma A/S a buy according to analysts?
The consensus of 18 analysts is a Buy rating, with an average 12-month price target of 310.69, which implies 22.9% upside from the current price. This is not investment advice.
What is Ascendis Pharma A/S's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Ascendis Pharma A/S a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Ascendis Pharma A/S discussion 0 comments